Navigation Links
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Date:6/19/2008

Company's Next-Generation Cephalosporin Effective Against

Difficult-to-Treat Skin Infections, Including Those with

methicillin-resistant Staphylococcus aureus (MRSA)

NEW YORK, June 19 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI). In both the CANVAS I and CANVAS II studies, ceftaroline as monotherapy achieved the primary endpoint of non-inferiority versus the combination of vancomycin plus aztreonam. Ceftaroline was generally well tolerated. Detailed results are expected to be presented later this year at a medical conference.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

"We are extremely pleased with the top-line results demonstrating ceftaroline's efficacy in treating complicated skin and skin structure infections, particularly in difficult to treat patients," said Howard Solomon, Chief Executive Officer of Forest Laboratories. "We recognize the urgent need for new broad-spectrum antibiotics such as ceftaroline to treat the growing number of serious infections involving resistant gram-positive pathogens such as MRSA, and gram-negative pathogens. The positive results of these Phase III ceftaroline trials are an important step in advancing Forest's pipeline, including our commitment to building a robust antibiotic franchise."

Design and Results

The two glob
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
3. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Romark Laboratories Raises $18 Million in Institutional Financing
11. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 /PRNewswire-iReach/ -- Phoenix Houses of ... abuse services organization, is hosting its tenth annual "Triumph ... on June 6, 2013.  More than 300 people are ... the adolescent residential treatment centers, family therapy, and prevention ... whose accomplishments have positive influences on the health and welfare ...
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
(Date:5/23/2013)... , May 24, 2013 3SBio Inc. ... "Company"), a leading China -based ... marketing biopharmaceutical products, announced today that, at an ... Company,s shareholders voted in favor of the proposal ... and plan of merger dated February 8, 2013, ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 43SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... -- The Six-Month Primary Efficacy Endpoint ... Significantly Increased "ON" Time in,Levodopa-Treated Patients With mid- to Late-Stage ... Endpoints of the Study Analyzed to Date Were met in,Both ... a division of Merck KGaA, Darmstadt, Germany, and its,partner Newron ...
... NEW YORK, Feb. 2 A study led by ... has identified a gene associated with the development of ... With funding provided by the Dystonia Medical Research Foundation ... mutations in the THAP1 gene cause DYT6 dystonia in ...
Cached Medicine Technology:Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 2Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 3Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 4Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 5Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 6Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder 2
(Date:5/24/2013)... Beach, Delaware (PRWEB) May 24, 2013 ... Mushrush has joined the Dayna Feher team at the ... Mushrush made the Delaware resorts her home in 1975. ... has since worked in all aspects of the real ... and for the past 12 years, a licensed sales ...
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout season has ... tips to help prevent grill fires throughout the spring and ... reports that gas grills led to an average of 7,100 ... grills, meanwhile, caused approximately 1,200 home fires per year during ... sharing the following tips from the NFPA to help protect ...
(Date:5/24/2013)... News) -- New research suggests a link between ... insomnia. Every additional hour someone with insomnia ... in the likelihood of moderate or high risk ... of Pennsylvania. "We were surprised by ... and suicide risk," study author, Linden Oliver, clinical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 CHI-California ... Appropriators and the California congressional delegation, joined by ... sequestered industry user fees paid to the U.S. ... ensure that future across-the-board cuts will not include ... the FY14 Agriculture, Rural Development and FDA Appropriations ...
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2
... /CTL/ -- CareToLive, a not for,profit corporation, received a ... its fight against the FDA on behalf of terminal ... an,appeal in the 6th Circuit Court in Ohio., ... outside of,their grasp," said CareToLive spokesperson, Melody Davis. "Congress ...
... N.J., Nov. 26 Quest Diagnostics,Incorporated (NYSE: ... information and services, announced that it is scheduled ... Conference at the Merrill,Lynch Headquarters in New York ... presentation is scheduled to begin at 10:15 a.m. ...
... are not the best for them, study says , , ... third of prostate cancer patients may receive treatments that ... with urinary, bowel or sexual function, a new study ... give enough information to their doctor or because their ...
... NASDAQ: CRME TSX: COM, VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ ... announced updated guidance for expected,interim results from its Phase ... to complete and disclose the interim,analysis in the fourth ... disclose the interim analysis in March 2008, with the ...
... (p. 30). Senior Writer Suzanne Smalley looks at,GOP presidential ... code, which is at once rigid (in public) and ... adult personality,can be traced back to his childhood and ... family of cops and hoods and to a Catholic ...
... dental care can even start in the womb, experts say ... of Americans is improving as people take better care of ... of the country,s most vulnerable individuals -- children. , Studies ... One federal report found that decay in baby teeth among ...
Cached Medicine News:Health News:CareToLive Reports: The FDA Fiddles While 30,000 Men Burn 2Health News:CareToLive Reports: The FDA Fiddles While 30,000 Men Burn 3Health News:Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference 2Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 2Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 3Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 4Health News:Cardiome Updates Guidance 2Health News:Cardiome Updates Guidance 3Health News:Cardiome Updates Guidance 4Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 2Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 3Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 4Health News:Tooth Decay Is Kids' Stuff 2Health News:Tooth Decay Is Kids' Stuff 3
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Ballard trach care HMES and filters, universal use, "Y" filter, CO 2 sampling port...
Medicine Products: